ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial.
作者信息
Kfoury M, Oing C
机构信息
Department of Oncology, Gustave Roussy Cancer Center, Villejuif, France.
Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Mildred Scheel Cancer Career Center, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
出版信息
ESMO Open. 2021 Feb;6(1):100025. doi: 10.1016/j.esmoop.2020.100025. Epub 2021 Jan 4.
Abstract
摘要
相似文献
1
ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial.ESMO面向青年肿瘤学家的20年回顾：转移性肾细胞癌的亮点——CheckMate-9ER试验
ESMO Open. 2021 Feb;6(1):100025. doi: 10.1016/j.esmoop.2020.100025. Epub 2021 Jan 4.
2
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.纳武利尤单抗联合伊匹单抗的疗效根据 CheckMate 214 中 IMDC 风险因素的数量。
Eur Urol. 2020 Apr;77(4):449-453. doi: 10.1016/j.eururo.2019.10.025. Epub 2019 Nov 13.
3
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自一项随机、对照、III 期临床试验的疗效和安全性结果的扩展随访。
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16.
4
Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial.转移性肾细胞癌的双重免疫检查点抑制：编者按：纳武利尤单抗联合伊匹木单抗与舒尼替尼用于晚期肾细胞癌一线治疗：III期CheckMate 214试验的4年延长随访
ESMO Open. 2021 Feb;6(1):100035. doi: 10.1016/j.esmoop.2020.100035. Epub 2021 Jan 7.
5
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼一线治疗中低危晚期肾细胞癌的成本效果分析。
Oncologist. 2019 Mar;24(3):366-371. doi: 10.1634/theoncologist.2018-0656. Epub 2019 Feb 1.
6
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于既往未治疗的晚期肾细胞癌：CheckMate 214 研究中日本患者的分析结果，随访时间延长。
Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.
7
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
8
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼治疗晚期肾细胞癌患者的患者报告结局（CheckMate 214）：一项随机、III 期试验。
Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15.
9
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.CheckMate 025 随机 3 期研究：纳武利尤单抗对比依维莫司治疗晚期肾细胞癌的关键基线因素和既往治疗的结局。
Eur Urol. 2017 Dec;72(6):962-971. doi: 10.1016/j.eururo.2017.02.010. Epub 2017 Mar 3.
10
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.纳武单抗对伴有肉瘤样分化的转移性嫌色细胞肾细胞癌有显著疗效：一例报告
BMC Urol. 2018 Apr 18;18(1):26. doi: 10.1186/s12894-018-0339-2.
引用本文的文献
1
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.免疫治疗后行肾切除术的晚期肾细胞癌患者的病理结果。
Oncologist. 2024 Oct 3;29(10):870-877. doi: 10.1093/oncolo/oyad166.
2
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.一线治疗成人晚期肾细胞癌：系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
3
Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance.VHL/HIF-α信号通路在肾透明细胞癌进展中的下游靶点：机制与治疗意义
Cancers (Basel). 2023 Feb 19;15(4):1316. doi: 10.3390/cancers15041316.
4
Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy.PD-1/PD-L1阻断疗法治疗肾细胞癌（RCC）的临床潜力：一种快速发展的策略。
Cancer Cell Int. 2022 Dec 12;22(1):401. doi: 10.1186/s12935-022-02816-3.
5
Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice.转移性肾细胞癌的管理：从分子机制到临床实践
Front Oncol. 2021 Apr 22;11:657639. doi: 10.3389/fonc.2021.657639. eCollection 2021.
Zotero 插件